|1.||Itoh, Kyogo: 12 articles (11/2009 - 05/2002)|
|2.||Harada, Mamoru: 8 articles (05/2015 - 07/2003)|
|3.||Berzofsky, Jay A: 7 articles (01/2013 - 04/2004)|
|4.||Reiter, Yoram: 7 articles (04/2012 - 07/2002)|
|5.||Romero, Pedro: 7 articles (10/2010 - 05/2002)|
|6.||Shichijo, Shigeki: 7 articles (11/2009 - 05/2002)|
|7.||Noguchi, Masanori: 7 articles (11/2009 - 07/2003)|
|8.||Speiser, Daniel E: 6 articles (01/2014 - 10/2002)|
|9.||Kiessling, Rolf: 6 articles (01/2011 - 11/2002)|
|10.||Knuth, Alexander: 6 articles (10/2010 - 01/2002)|
08/12/1998 - "We report here that not only monocyte-derived dendritic cells but also activated T cells incubated with the MAGE-3 antigenic peptide presented by HLA-A2 were effective in activating specific CTL precursors present in the blood of individuals without cancer. "
01/01/2007 - "Here we report the results of a phase I clinical study of intensive course NY-ESO-1 peptide vaccination, evaluating the safety, immunogenicity and clinical response in HLA-A2 positive patients with NY-ESO-1 expressing cancers. "
09/01/2005 - "Binding studies revealed its ability to decorate Ag-positive human tumor cells with covalent peptide single-chain HLA-A2 (scHLA-A2) molecules in a manner that was entirely dependent upon the specificity of the targeting Antibody fragment. "
04/25/2000 - "The objectives of the present study were (i) to develop enzyme-linked immunospot (ELISPOT) and tetramer assays to measure CD8(+) T cell responses to NY-ESO-1, (ii) to determine the frequency of CD8(+) T cell responses to NY-ESO-1 in a series of HLA-A2 patients with NY-ESO-1 expressing tumors, (iii) to determine the relation between CD8(+) T cell and humoral immune responses to NY-ESO-1, and (iv) to compare results of NY-ESO-1 ELISPOT assays performed independently in two laboratories with T cells from the same patients. "
02/15/1994 - "Results from in vitro studies of immune response to Epstein-Barr virus have found that the HLA-A2 antigen efficiently presents the EBV gene product LMP-2, which has been detected in NPC tumor cells. "
|2.||Melanoma (Melanoma, Malignant)
07/01/2003 - "Seven HLA-A2 patients with metastatic melanoma-two classified as M1 and five as M3-were included in the study. "
07/15/1995 - "In this study, a model was developed in which clones derived from the 624-MEL melanoma cell line and expressing varying amounts of HLA-A2 molecules were lysed in a standard 51Cr release assay by an HLA-A2-restricted CTL clone (A42) or a bulk culture of tumor-infiltrating lymphocytes. "
08/01/1993 - "These studies provide important information for the studying immunization of patients with HLA-A2 melanoma with an allogeneic HLA-A2 MCV in a Phase I clinical trial."
01/01/2014 - "Retargeted T cells expressing GPA7-28z could exhibit efficient cytotoxic activities against human melanoma cells in vitro in the context with HLA-A2. "
11/01/2013 - "The engineered NK-92MI-GPA7-ζ cells could recognize melanoma cells in the context of HLA-A2 and showed enhanced killing of both melanoma cell lines and primary melanoma. "
02/15/2003 - "Therefore, in the HLA-A2 context, clonal expansions of anti-IE1 memory CTLs may confer a protection against HCMV successive infections and reactivations by killing cells presenting most of the naturally occurring IE1(315-324) epitope variants."
06/01/2009 - "We propose that the newly identified CTL epitope restricted by HLA-A2.1 could aid in further study of RV-associated infection in humans."
07/01/2015 - "The HCMV UL83/pp65-derived NLV-peptide was presented by transgenic HLA-A2.1 in the context of a lethal infection of NOD/SCID/IL-2rg-/- mice with a chimeric murine CMV, mCMV-NLV. "
01/01/2012 - "The region responsive towards DV infection of all serotypes was mapped to the Class I Regulatory Complex (CRC) of the HLA-A2 promoter. "
04/15/2010 - "Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection."
|4.||Neoplasm Metastasis (Metastasis)
11/01/2009 - "HLA-A2 was an independent risk factor for lymph node and distant metastasis, and the allele was significantly higher in patients with critical lymph node for surgery and distant metastasis. "
11/01/2009 - "HLA-A2 was an independent risk factor for both critical lymph node (N(2 and 3)) involvement and distant metastasis. "
11/01/1991 - "HLA-A2 expression was absent or reduced in 4/4 colon tumours and all their metastases. "
06/01/2005 - "Tumor cells in the first metastasis escaped immune recognition via selective loss of an HLA haplotype (HLA-A11, -B44, and -Cw17), but maintained expression of HLA-A2. "
07/19/1999 - "HLA-A2 antigen is selectively lost in primary melanoma lesions and more frequently in metastases. "
07/01/2015 - "Importantly, the Gag-specific Gag-Texo/4-1BBL vaccine also stimulates more efficient Gag-specific therapeutic and long-term immunity against HLA-A2/Gag-expressing B16 melanoma BL6-10Gag/A2 cells than the control Gag-Texo/Null vaccine in transgenic HLA-A2 mice. "
04/01/2011 - "HLA-A2 transgenic mice bearing established HLA-A2(neg) B16 melanomas were effectively treated by intratumoral (i.t.) injection of syngeneic dendritic cells (DCs) transduced to express high levels of interleukin (IL)-12, resulting in CD8(+) T cell-dependent antitumor protection. "
05/21/2012 - "In addition, Gp120-Texo vaccine also induces Gp120-specific preventive, therapeutic (for 6 day tumor lung metastasis) and CD4(+) T cell-independent long-term immunity against B16 melanoma BL6-10(Gp120/A2Kb) expressing both Gp120 and A2Kb (α1 and α2 domains of HLA-A2 and α3 domain of H-2K(b)) in Tg HLA-A2 mice. "
|5.||HLA-A3 Antigen (HLA A3 Antigen)
|6.||T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)
|7.||DNA (Deoxyribonucleic Acid)
|9.||Proteins (Proteins, Gene)
|2.||Transplantation (Transplant Recipients)
|3.||Homologous Transplantation (Allograft)